RESUMO
We reviewed the history, volume, outcomes, uniqueness, and challenges of living donor liver transplantation (LDLT) in Latin America. We used the data from the Latin American and Caribbean Transplant Society, local transplant societies, and opinions from local transplant experts. There are more than 160 active liver transplant teams in Latin America, but only 30 centers have used LDLT in the past 2 years. In 2014, 226 LDLTs were done in the region (8.5% of liver transplant activities). Living donor liver transplantation is mainly restricted to pediatric patients. Adult-to-adult LDLT activities decreased after the implementation of the model for end-stage liver disease score and a concomitant increase on the rate of deceased donors per million population. Posttransplant outcome analysis is not mandatory, transparent or regulated in most countries. More experienced teams have outcomes comparable to international expert centers, but donor and recipient morbidity might be underreported. Latin America lags behind in terms of the number of adult LDLT and the rate of living donor utilization in comparison with other continents with similar donation rates. Local alliances and collaborations with major transplant centers in the developed world will contribute to the development of LDLT in Latin America.
Assuntos
Doença Hepática Terminal/cirurgia , Transplante de Fígado/métodos , Doadores Vivos , Brasil , Doença Hepática Terminal/etnologia , Humanos , Relações Interinstitucionais , Cooperação Internacional , América Latina , Índice de Gravidade de Doença , Obtenção de Tecidos e Órgãos , Resultado do TratamentoRESUMO
BACKGROUND: The model for end-stage liver disease (MELD) is based on objective variables, including serum creatinine (SCr). This study assesses the influence of skin color on MELD scores calculated using SCr or corrected creatinine (CrC) in female candidates for liver transplantation (LTx). METHODS: White and black women were eligible. The glomerular filtration rate (GFR) was calculated by means of the Modification of Diet in Renal Disease formula, using SCr. The GFR was then used for reverse calculation of CrC considering each female as male. The MELD scores were calculated using both creatinine values and compared between white and black candidates. RESULTS: SCr-based and CrC-based scores were similar between groups. Calculated GFR was significantly higher in black women than in white women (P < 0.001). Use of CrC yielded 1-point, 2-point, and 3-point increases in the MELD score in 20.2%, 25.7%, and 17.5% of white patients, respectively. None of the black patients had a MELD score increase greater than 1 point. The CrC-based MELD calculation would benefit 63.4% of white females and only 26.1% of black females. CONCLUSIONS: Use of CrC for MELD calculation would prioritize white females for liver allocation, but does not seem feasible, as it would not ensure equitable allocation across different ethnicities.